专利检索_·脲基的氮原子连接非环碳原子专利检索_·脲基的氮原子连接非环碳原子专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
341	RETROVIRAL PROTEASE INHIBITORS	GR970402230	1997-08-29	GR3024586T3	1997-12-31	DECRESCENZO GARY ANTHONY; FRESKOS JOHN NICHOLAS; GETMAN DANIEL PAUL; LIN KO-CHUNG; ROGIER DONALD JOSEPH JR; TALLEY JOHN JEFFREY

342		PT9846491	1991-07-26	PT98464B	1997-10-31	VORBRUGGEN HELMUT; KLAR ULRICH; REHWINKEL HARTMUT; THIERAUCH KARL-HEINZ; VERHALLEN PETER

343	Retroviral protease inhibitors	DK92901691	1991-11-18	DK0558657T3	1997-07-07	TALLEY JOHN JEFFREY; REED KATHRYN LEA

344	Retroviral protease inhibitors	DE69124110	1991-11-18	DE69124110T2	1997-06-05	REED KATHRYN; TALLEY JOHN

345	Cyclopentane derivatives process for their production and their pharmaceutical use	IE265591	1991-07-29	IE73476B1	1997-06-04	KLAR ULRICH DR; REHWINKEL HARTMUT DR; VORBRUGGEN HELMUET PROF; THIERAUCH KARL-HEINZ DR; VERHALLEN PETER DR

346	Benzocycloalkene compounds with melatonine receptor binding affinity, their production and use	AU6531296	1996-07-25	AU6531296A	1997-02-26	OHKAWA SHIGENORI; UCHIKAWA OSAMU; FUKATSU KOHJI; MIYAMOTO MASAOMI

347	Retroviral protease inhibitors	DE69124110	1991-11-18	DE69124110D1	1997-02-20	REED KATHRYN; TALLEY JOHN

348	UREIDS DERIVED FROM ALPHA, OMEGA-DIAMINO-ACIDS AND PROCESS FOR PRODUCING THEM	HU9401821	1994-06-17	HUT71414A	1995-11-28	CALLENS ROLAND; BLONDEEL GEORGES; ANTEUNIS MARC; BECU FRANK

349	Cyclopentene derivatives, methods for their manufacture and their pharmaceutical use.	DE59106490	1991-07-22	DE59106490D1	1995-10-19	KLAR ULRICH; REHWINKEL HARTMUT; VORBRUEGGEN HELMUT; THIERAUCH KARL-HEINZ; VERHALLEN PETER

350	Cyclopentane derivatives, processes for their preparation and pharmaceutical use.	ES91912997	1991-07-22	ES2074721T3	1995-09-16	KLAR ULRICH DR; REHWINKEL HARTMUT DR; VORBRUGGEN HELMUT PROF; THIERAUCH KARL-HEINZ DR; VERHALLEN PETER DR
LA INVENCION SE REFIERE A DERIVADOS DEL CICLOPENTANO DE LA FORMULA (I) EN LA QUE HAY UN DOBLE ENLACE ENTRE LOS ATOMOS DE CARBONO DE CENTROS AB O CD, YA SUS SALES CON BASES TOLERABLES FISIOLOGICAMENTE, ASI COMO LOS CICLODEXTRINA CLATRATOS (ALFA), (BETA) OY, ASI COMO LOS COMPUESTOS ENCAPSULADOS CON LIPOSOMAS DE LA FORMULA (I), PROCESO PARA SU FABRICACION Y SU EMPLEO FARMACEUTICO.
351	Retroviral protease inhibitors	AU9133291	1991-11-18	AU662309B2	1995-08-31	REED KATHRYN LEA; TALLEY JOHN JEFFREY

352	Use of urea-derivatives as crystallization inhibitors	DE4341984	1993-12-09	DE4341984A1	1995-06-14	WIRTH WOLFGANG DIPL CHEM DR; WANGERMANN KLAUS DIPL PHYS DR; BOTTA ARTUR DIPL CHEM DR; REIZLEIN KARL DIPL CHEM DR; ROSENFELDT FRANK DIPL CHEM DR

353	GLYCOSAMINOGLYCAN SALTS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM	CA601668	1989-06-02	CA1335375C	1995-04-25	DAL POZZO ALMA; ACQUASALIENTE MAURIZIO; SPORTOLETTI GIANCARLO; SARRET MONIQUE; FERRUTI PAOLO; DE SANTIS FRANCESCO
Salts of glycosaminoglycans (heparin, its fractions or fragments "supersulfatated", dermatan sulfate, heparan sulfate, modified heparins) with cations of formula I (I) wherein R1, R2, R3 and R4 represent for instance H, alkyl, cycloalkyl; R5 and R6 represent H, alkyl or aryl; R7 and R8 represent H or alkyl; n and m range from 1 to 4 whereas X = -O-CO-O-; -O-CO-; -NH-CO-; -NH-CO-NH- etc., show the typical pharmacological properties of the glycosaminoclycans themselves also by oral or rectal administration.
354	PROCESS FOR THE PREPARATION OF THALIDOMIDE	CA2531868	1994-07-01	CA2531868A1	1995-01-12	MULLER GEORGE W
The present invention relates to compounds which are useful for reducing levels of TNF.alpha. in a mammal. Examples of compounds include those of formula: See formula 1 wherein, for example, R7 is a cyclic alkyl, a substituted phenyl, etc ...; n is 1 and R12 is an alkoxy, a disubstituted amino, etc ...; those of formula: See formula 2 wherein, for example, Z is See formula 3 n is 1, 2 or 3; R1 is a divalent residue of 3,4-pyridine, pyrrolidine, etc ...; R2 is -CO- or -SO2-; R3 is a substituted phenyl, pyridyl, etc ...; and R4 is alanyl, argynyl, etc ...; or those of formula: wherein, for example, an optionally substituted o-phenylene, a divalent residue of pyridine, etc ...; R6 is -CO-, -CH2- or -SO2-; R7 is pyridyl, substituted phenyl etc ...; and R12 is -OH, alkoxy, etc ...;
355	Retroviral protease inhibitors.	ES92901068	1991-11-18	ES2059295T1	1994-11-16	CLARE MICHAEL; DECRESCENZO GARY ANTHONY; FRESKOS JOHN NICHOLAS; GETMAN DANIEL PAUL; HEINTZ ROBERT MARTIN; LIN KO-CHUNG; MUELLER RICHARD AUGUST; REED KATHRYN LEA; TALLEY JOHN JEFFREY; VAZQUEZ MICHAEL LAWRENCE; SUN ERIC TAK ON
COMPUESTOS REPRESENTADOS POR LA FORMULA (I), DONDE A REPRESENTA RADICALES REPRESENTADOS POR LAS FORMULAS (A1,A2,A3), (VALORES PARA LAS VARIABLES DADAS AQUI), SON EFICACES COMO INHIBIDORES DE PROTEASA RETROVIRAL, Y EN PARTICULAR COMO INHIBIDORES DE PROTEASA HIV.
356	Retroviral protease inhibitors.	ES92900484	1991-11-18	ES2059289T1	1994-11-16	DECRESCENZO GARY ANTHONY; FRESKOS JOHN NICHOLAS; GETMAN DANIEL PAUL; LIN KO-CHUNG; ROGIER DONALD JOSEPH JR; TALLEY JOHN JEFFREY
COMPUESTOS REPRESENTADOS POR LA FORMULA (I) EN LA QUE A REPRESENTA R, R13 Y RADICALES REPRESENTADOS POR LA FORMULA (II), B REPRESENTA R5 Y RADICALES REPRESENTADOS POR LA FORMULA (III) (VALORES PARA LAS VARIABLES DADAS AQUI), SON EFICACES COMO INHIBIDORES DE LA PROTEASA RETROVIRAL Y EN PARTICULAR COMO INHIBIDORES DE LA PROTEASA HIV.
357		MX9102137	1991-11-19	MX9102137A	1994-03-31	HEINTZ ROBERT MARTIN; LIN KO-CHUNG; ROGIER DONALD JOSEPH JR; TALLEY JOHN JEFFREY; DERTENSHAW DEBORAH ELIZABETH; FRESKOS JOHN NICHOLAS; GETMAN DANIEL PAUL

358		MX9102136	1991-11-19	MX9102136A	1994-01-31	REED KATHRYN LEA; TALLEY JOHN JEFFREY

359	Selected difluoro derivatives	IE151386	1986-06-06	IE59146B1	1994-01-12

360	INHIBITORS OF RETROVIRUS PROTEASE	HU144593	1991-11-18	HU9301445D0	1993-11-29	REED KATHRYN LEA; TALLEY JOHN JEFFREY

13 14 15 16 17 18 19 20 21 22

该功能需要专业版企业版VIP权限，您可以：